Genelux Corp (GNLX) — insider trading
Health Care · NASDAQ
Genelux Corp (GNLX) has 26 reported SEC Form 4 insider transactions in our data, including 13 open-market sales among the most recent 26 (latest 2026-08-31).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-31 | Zindrick Thomas | Officer (President and CEO) | Open-market sale | 34,463 | $2.67 | $91.9K | Form 4 |
| 2026-08-31 | Yu Yong | Officer (Chief Scientific Officer) | Open-market sale | 9,683 | $2.75 | $26.7K | Form 4 |
| 2026-08-31 | Cappello Joseph | Officer (Chief Technical Officer) | Open-market sale | 10,257 | $2.74 | $28.1K | Form 4 |
| 2026-08-04 | Zindrick Thomas | Officer (President and CEO) | Open-market sale | 3,023 | $2.95 | $8.9K | Form 4 |
| 2026-08-04 | Cappello Joseph | Officer (Chief Technical Officer) | Open-market sale | 653 | $2.95 | $1.9K | Form 4 |
| 2026-08-04 | Yu Yong | Officer (Chief Scientific Officer) | Open-market sale | 653 | $2.94 | $1.9K | Form 4 |
| 2026-07-01 | Smither John W | Director | Open-market sale | 12,000 | $2.91 | $34.9K | Form 4 |
| 2026-06-16 | Smither John W | Director | Grant / award / vesting (derivative) | 31,566 | — | $0 | Form 4 |
| 2026-06-16 | Smither John W | Director | Grant / award / vesting | 28,409 | — | $0 | Form 4 |
| 2026-06-16 | Yu Yong | Officer (Chief Scientific Officer) | Grant / award / vesting | 119,318 | — | $0 | Form 4 |
| 2026-06-16 | Mirabelli Mary | Director | Grant / award / vesting (derivative) | 31,566 | — | $0 | Form 4 |
| 2026-06-16 | Mirabelli Mary | Director | Grant / award / vesting | 28,409 | — | $0 | Form 4 |
| 2026-06-16 | Thomas John | Director | Grant / award / vesting (derivative) | 31,566 | — | $0 | Form 4 |
| 2026-06-16 | Thomas John | Director | Grant / award / vesting | 28,409 | — | $0 | Form 4 |
| 2026-06-16 | Zindrick Thomas | Officer (President and CEO) | Grant / award / vesting | 730,601 | — | $0 | Form 4 |
| 2026-06-16 | Tyree James L | Director | Grant / award / vesting (derivative) | 31,566 | — | $0 | Form 4 |
| 2026-06-16 | Tyree James L | Director | Grant / award / vesting | 28,409 | — | $0 | Form 4 |
| 2026-06-16 | Cappello Joseph | Officer (Chief Technical Officer) | Grant / award / vesting | 174,841 | — | $0 | Form 4 |
| 2026-06-16 | Groen Eric | Officer (General Counsel) | Grant / award / vesting | 233,957 | — | $0 | Form 4 |
| 2026-06-16 | Pulisic Matthew | Officer (Chief Financial Officer) | Grant / award / vesting | 278,906 | — | $0 | Form 4 |
| 2026-06-03 | Smalling Ralph | Officer (Head of Regulatory) | Open-market sale | 192 | $2.93 | $563 | Form 4 |
| 2026-06-01 | Thomas John | Director | Open-market sale | 10,000 | $2.98 | $29.8K | Form 4 |
| 2026-05-11 | Smalling Ralph | Officer (Head of Regulatory) | Open-market sale | 270 | $2.98 | $804 | Form 4 |
| 2026-05-11 | Zindrick Thomas | Officer (President and CEO) | Open-market sale | 2,798 | $2.94 | $8.2K | Form 4 |
| 2026-05-11 | Cappello Joseph | Officer (Chief Technical Officer) | Open-market sale | 605 | $2.97 | $1.8K | Form 4 |
| 2026-05-11 | Yu Yong | Officer (Chief Scientific Officer) | Open-market sale | 605 | $2.97 | $1.8K | Form 4 |
Ask the chat about GNLX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Genelux Corp (GNLX).
Last updated 2026-08-31 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.